{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:36:44Z","timestamp":1784547404703,"version":"3.55.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["Z1A AA000466"],"award-info":[{"award-number":["Z1A AA000466"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.05.031","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T11:33:00Z","timestamp":1496143980000},"page":"73-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["The endocannabinoid system as a target for addiction treatment: Trials and tribulations"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-8802","authenticated-orcid":false,"given":"Matthew E.","family":"Sloan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Gowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay A.","family":"Ramchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin L.","family":"Hurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.05.031_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib2","doi-asserted-by":"crossref","first-page":"e44864","DOI":"10.1371\/journal.pone.0044864","article-title":"Quantifying the clinical significance of cannabis withdrawal","volume":"7","author":"Allsop","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib3","first-page":"Cd003409","article-title":"Methadone at tapered doses for the management of opioid withdrawal","author":"Amato","year":"2013","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002130050326","article-title":"Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors","volume":"132","author":"Arnone","year":"1997","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2015.19284","article-title":"Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 Weeks: a randomized clinical trial","volume":"315","author":"Baker","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1369-1600.2011.00427.x","article-title":"Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers","volume":"18","author":"Bedi","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. drug Saf."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib11","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/jcbfm.2015.133","article-title":"Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB","volume":"35","author":"Boileau","year":"2015","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","article-title":"Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms","volume":"86","author":"Budney","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib13","first-page":"Cd006103","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2016","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib14","first-page":"Cd009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib15","first-page":"Cd005353","article-title":"Cannabinoid type 1 receptor antagonists for smoking cessation","author":"Cahill","year":"2011","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib16","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1523\/JNEUROSCI.4403-06.2007","article-title":"Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration","volume":"27","author":"Caille","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","article-title":"SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats","volume":"13","author":"Cohen","year":"2002","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/oxfordjournals.alcalc.a008368","article-title":"Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716","volume":"33","author":"Colombo","year":"1998","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002130100887","article-title":"Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats","volume":"159","author":"Colombo","year":"2002","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bpsc.2015.09.008","article-title":"Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis","volume":"1","author":"D'Souza","year":"2016","journal-title":"Biol. Psychiatry Cognitive Neurosci. Neuroimaging"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.104.001313","article-title":"Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors","volume":"66","author":"Damaj","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib26","series-title":"EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ACOMPLIA: EPAR Summary for the Public","author":"EMA","year":"2007"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib27","series-title":"European Medicines Agency: PUBLIC STATEMENT on Acomplia (Rimonabant) WITHDRAWAL of the MARKETING AUTHORISATION IN the EUROPEAN UNION","author":"EMA","year":"2009"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1615\/CritRevNeurobiol.v16.i12.160","article-title":"Cannabinoids and reward: interactions with the opioid system","volume":"16","author":"Fattore","year":"2004","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib29","series-title":"FDA Finds Drugs under Investigation in the U.S. Related to French BIA 10-2474 Drug Do Not Pose Similar Safety Risks","author":"FDA","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1530-0277.2009.01074.x","article-title":"CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats","volume":"34","author":"Femenia","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00213-009-1569-5","article-title":"Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration\u2013comparison with CB(1) receptor blockade","volume":"205","author":"Forget","year":"2009","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00213-005-0015-6","article-title":"Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats","volume":"181","author":"Forget","year":"2005","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Forouzanfar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib34","doi-asserted-by":"crossref","first-page":"e29900","DOI":"10.1371\/journal.pone.0029900","article-title":"Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking","volume":"7","author":"Gamaleddin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-009-1704-3","article-title":"Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers","volume":"208","author":"George","year":"2010","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"42","key":"10.1016\/j.neuropharm.2017.05.031_bib36","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.2174\/1381612822666160822150822","article-title":"Pharmacological treatment of cannabis-related disorders: a narrative review","volume":"22","author":"Gorelick","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib37","first-page":"Cd002025","article-title":"Buprenorphine for managing opioid withdrawal","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib38","first-page":"Cd002024","article-title":"Alpha(2)-adrenergic agonists for the management of opioid withdrawal","author":"Gowing","year":"2016","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.neuron.2016.04.043","article-title":"Endocannabinoid modulation of orbitostriatal circuits gates habit formation","volume":"90","author":"Gremel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/mp.2012.72","article-title":"Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity","volume":"18","author":"Gunduz-Cinar","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/npp.2013.54","article-title":"Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","article-title":"Marijuana withdrawal in humans: effects of oral THC or divalproex","volume":"29","author":"Haney","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib45","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.05.031_bib46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the national epidemiologic survey on alcohol and related conditions\u2013III","volume":"173","author":"Hasin","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib47","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s00213-016-4298-6","article-title":"Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users","volume":"233","author":"Herrmann","year":"2016","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib48","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib51","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"Huggins","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib52","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1046\/j.1471-4159.2003.01576.x","article-title":"Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens","volume":"84","author":"Hungund","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib54","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-013-3117-6","article-title":"The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice","volume":"229","author":"Ignatowska-Jankowska","year":"2013","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.drugalcdep.2015.09.031","article-title":"Safety of oral dronabinol during opioid withdrawal in humans","volume":"157","author":"Jicha","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib56","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib57","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1038\/npp.2008.21","article-title":"Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant","volume":"33","author":"Justinova","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib58","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.bjp.0703987","article-title":"Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice","volume":"132","author":"Kathmann","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib60","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bcp.12071","article-title":"Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Delta9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib62","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib63","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(97)01160-6","article-title":"SR141716A is an inverse agonist at the human cannabinoid CB1 receptor","volume":"334","author":"Landsman","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib64","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/bs.pbr.2015.11.001","article-title":"What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses","volume":"224","author":"Le Foll","year":"2016","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib66","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/00001756-200409150-00028","article-title":"Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences","volume":"15","author":"Le Foll","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib67","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl.\u00a0B","key":"10.1016\/j.neuropharm.2017.05.031_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(82)80031-5","article-title":"Pharmacokinetics, metabolism and drug-abuse potential of nabilone","volume":"9","author":"Lemberger","year":"1982","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib71","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","article-title":"Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects","volume":"73","author":"Li","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib72","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-3565(24)29469-6","article-title":"Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice","volume":"298","author":"Lichtman","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2016.05.002","article-title":"Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans","volume":"164","author":"Lofwall","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nchembio.129","article-title":"Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects","volume":"5","author":"Long","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib75","doi-asserted-by":"crossref","first-page":"20270","DOI":"10.1073\/pnas.0909411106","article-title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in\u00a0vivo","volume":"106","author":"Long","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib76","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J.\u00a0Addict. Med."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib77","first-page":"Cd008940","article-title":"Pharmacotherapies for cannabis dependence","author":"Marshall","year":"2014","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib78","first-page":"Cd002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib79","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/mp.2012.145","article-title":"Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity","volume":"18","author":"Meye","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature19785","article-title":"X-ray structure of the human alpha4beta2 nicotinic receptor","volume":"538","author":"Morales-Perez","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib81","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib82","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-010-1790-2","article-title":"Randomized, controlled, double-blind trial of taranabant for smoking cessation","volume":"209","author":"Morrison","year":"2010","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib83","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bph.12948","article-title":"Inhibition of monoacylglycerol lipase reduces nicotine withdrawal","volume":"172","author":"Muldoon","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib84","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2013.157","article-title":"Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine","volume":"38","author":"Navarrete","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/AJP.0b013e318219799a","article-title":"A\u00a0randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction","volume":"27","author":"Ostenfeld","year":"2011","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib87","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0026-895X(25)09896-7","article-title":"Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit","volume":"45","author":"Papke","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signalling in reward and addiction","volume":"16","author":"Parsons","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib90","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib91","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/npp.2012.269","article-title":"Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice","volume":"38","author":"Ramesh","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib92","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.111.181370","article-title":"Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice","volume":"339","author":"Ramesh","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib93","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib94","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1360-0443.2008.02454.x","article-title":"A\u00a0randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain","volume":"104","author":"Rigotti","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib96","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2016.00422","article-title":"Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib98","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib99","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose Deaths\u2013United States, 2000-2014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib101","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/npp.2016.27","article-title":"Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys","volume":"41","author":"Schindler","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib102","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-009-9110-7","article-title":"Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice","volume":"11","author":"Schlosburg","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib103","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.neuropharm.2012.06.046","article-title":"AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid\/cannabinoid interaction studies","volume":"63","author":"Seely","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pharmthera.2011.06.005","article-title":"Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors","volume":"132","author":"Serrano","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.euroneuro.2009.11.002","article-title":"Potential anxiogenic effects of cannabinoid CB1 receptor antagonists\/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142","volume":"20","author":"Sink","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib106","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)38905-0","article-title":"Bupropion is a nicotinic antagonist","volume":"295","author":"Slemmer","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12491","article-title":"Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant","author":"Sloan","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","article-title":"Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial","volume":"28","author":"Soyka","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib109","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1099420","article-title":"Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization","volume":"306","author":"Tapper","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in\u00a0vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib111","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/0269881111431623","article-title":"Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial","volume":"26","author":"Tonstad","year":"2012","journal-title":"J.\u00a0Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib113","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib114","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00213-015-4117-5","article-title":"Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice","volume":"233","author":"Trigo","year":"2016","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib115","series-title":"The Endocannabinoid System: Genetics Biochemistry, Brain Disorders, and Therapy","article-title":"The role of the endocannabinoid system in addiction","author":"Trigo","year":"2017"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","article-title":"The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users","volume":"128","author":"Vandrey","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12495","article-title":"Cannabidiol reduces ethanol consumption, motivation and relapse in mice","author":"Viudez-Mart\u00ednez","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib119","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1073\/pnas.0336351100","article-title":"Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice","volume":"100","author":"Wang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13556210500222670","article-title":"How does bupropion work as a smoking cessation aid?","volume":"10","author":"Warner","year":"2005","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib121","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuropharm.2016.11.015","article-title":"The endocannabinoid hydrolysis inhibitor SA-57: intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice","volume":"114","author":"Wilkerson","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib122","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib123","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/npp.2014.297","article-title":"Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats","volume":"40","author":"Zhang","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib124","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.05.031_bib125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.05.031_bib126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/0269881108096509","article-title":"Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625","volume":"24","author":"Zuurman","year":"2010","journal-title":"J.\u00a0Psychopharmacol. Oxf. Engl."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T21:14:53Z","timestamp":1750281293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817302563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":126,"alternative-id":["S0028390817302563"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.031","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The endocannabinoid system as a target for addiction treatment: Trials and tribulations","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}